PA
TDOC icon

PharVision Advisers’s Teladoc Health TDOC Stock Holding History

PharVision Advisers’s Portfolio TDOC Stock Details TDOC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-31,473
Closed -$220K – 589
2025
Q4 		$220K Buy
+31,473
New +$246K 0.11% 480
2025
Q1 		– Sell
-33,100
Closed -$301K – 503
2024
Q4 		$301K Buy
+33,100
New +$320K 0.25% 150

Other funds holding TDOC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PharVision Advisers's TDOC Position: Q1 2026 in Review

PharVision Advisers sold out of Teladoc Health (TDOC) in Q1 2026, closing a stake of 31,473 shares — an estimated $220K sold.

PharVision Advisers first reported a position in TDOC in Q4 2024 and held it in 2 quarters. The position peaked at $301K in Q4 2024. 325 funds tracked by Wall St. Rank hold TDOC as of Q1 2026.

  • PharVision Advisers reported no remaining Teladoc Health position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 31,473 Teladoc Health shares in Q1 2026, an estimated $220K.
  • PharVision Advisers first reported a position in Teladoc Health in Q4 2024 and held it in 2 quarters.
  • PharVision Advisers's Teladoc Health position peaked at $301K in Q4 2024.
  • 325 funds tracked by Wall St. Rank held Teladoc Health as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.